India · Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 243.58 billion. The enterprise value is 288.06 billion.
| Market Cap | 243.58B |
| Enterprise Value | 288.06B |
Important Dates
The next estimated earnings date is Tuesday, October 28, 2025.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | Jul 16, 2025 |
Share Statistics
| Current Share Class | 1.33B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.48% |
| Shares Change (QoQ) | -0.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 600.75M |
Valuation Ratios
The trailing PE ratio is 248.37 and the forward PE ratio is 88.38.
| PE Ratio | 248.37 |
| Forward PE | 88.38 |
| PS Ratio | 2.67 |
| PB Ratio | 3.00 |
| P/TBV Ratio | 9.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 293.73 |
| EV / Sales | 3.15 |
| EV / EBITDA | 20.79 |
| EV / EBIT | 48.71 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.69 |
| Debt / FCF | n/a |
| Interest Coverage | 1.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 2.55% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 16.68M |
| Profits Per Employee | 179,091 |
| Employee Count | 5,476 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Piramal Pharma has paid 2.83 billion in taxes.
| Income Tax | 2.83B |
| Effective Tax Rate | 74.24% |
Stock Price Statistics
The stock price has decreased by -0.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -0.08% |
| 50-Day Moving Average | 198.78 |
| 200-Day Moving Average | 219.32 |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (20 Days) | 137,238 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 91.34 billion and earned 980.70 million in profits. Earnings per share was 0.73.
| Revenue | 91.34B |
| Gross Profit | 55.59B |
| Operating Income | 5.22B |
| Pretax Income | 3.81B |
| Net Income | 980.70M |
| EBITDA | 12.76B |
| EBIT | 5.22B |
| Earnings Per Share (EPS) | 0.73 |
Balance Sheet
The company has 4.09 billion in cash and 48.56 billion in debt, giving a net cash position of -44.48 billion.
| Cash & Cash Equivalents | 4.09B |
| Total Debt | 48.56B |
| Net Cash | -44.48B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 81.25B |
| Book Value Per Share | 61.35 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 60.86%, with operating and profit margins of 5.72% and 1.07%.
| Gross Margin | 60.86% |
| Operating Margin | 5.72% |
| Pretax Margin | 4.17% |
| Profit Margin | 1.07% |
| EBITDA Margin | 13.97% |
| EBIT Margin | 5.72% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.07%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.07% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -1.48% |
| Shareholder Yield | -1.40% |
| Earnings Yield | 0.40% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |